Document is current
Any future updates will be listed below
-
Authors
Damaj, Gandhi
de Masson, Adèle
Dreger, Peter
Bazarbachi, Ali
Berning, Philipp
Duarte, Rafael F.
Fox, Christopher P.
Guenova, Emmanuella
Hermine, Olivier
Kyriakou, Charalampia
Tanase, Alina
Tournilhac, Olivier
Jurczak, Wojiech
Karsten, Imke E.
Quoc, Stéphanie Nguyen
Serroukh, Yasmina
Stella, Federico
Wulf, Gerald
Sureda, Anna
Papadavid, Evangelia
Ortiz-Romero, Pablo L.
Ruggeri, Annalisa
Sánchez-Ortega, Isabel
Scarisbrick, Julia J.
Yakoub-Agha, Ibrahim
Onida, Francesco
Schmitz, Norbert
- License Information
-
More Information
Article History
Received: 10 April 2025
Accepted: 11 July 2025
First Online: 1 October 2025
Competing interests
: GD: Honoraria: Takeda, Amgen. Travel support: Takeda. Research Support: Takeda, Ideogen. ADM: Honoraria: Takeda, Kyowa Kirin, Helsinn, Recordati Rare Diseases, Almirall, Novartis. Travel support: Kyowa Kirin, Recordati Rare Diseases, Novartis. Research Support: Kyowa Kirin. PD: none reported. AB: Honoraria: Takeda, Amgen, Janssen, Roche, Maat Pharma Research Support: Takeda, Roche, Novartis, Janssen. PB: none reported. SF: none reported. RFD: none reported. CPF: Consultancy: AbbVie, Arvinas, Atarabio, BMS, GenMab, Gilead/Kite, Incyte, Lilly, Morphosys, Ono, Roche, SERB, SOBI, Takeda. Research funding: BeiGene, AbbVie/GenMab, Incyte. EG: honoraria and/or grant support from Mallinckrodt, Helsinn, Takeda Pharmaceuticals, Recordati Rare Diseases, Novartis, Sanofi, Stemline Therapeutics, and Kyowa Kirin. OH: Research fund, BMS, Bluueprint, Abbvie, Roche. CK: Research support BMS, Travel support Takeda. AT: Honoraria: Genesis Pharma, SOBI, Johnson & Johnson, Abbvie. OT: Honoraria: Takeda, BeiGene. Travel support: Takeda, Abbvie, Astra-Zeneca, BeiGene. Research Support: Takeda. WJ: Honoraria: Takeda, AbbVie. IEK: is supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—493624047 (Clinician Scientist CareerS Muenster), Honoraria: Kite/Gilead, Travel grants: BeiGene. SNQ: Honoraria: Jazz Pharma, Novartis, Abbvie, Gilead; Travel support: Abbvie, Gilead, Sanofi, Neovii. YS: none reported. GW: Honoraria: Takeda, Gilead Scienes, Novartis, Clinigen; Travel support: Medac, Janssen. AS: Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, GenMab, Abbvie, Jazz Pharmaceuticals, Therakos, Menarini; Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, Abbvie; Speaker’s Bureau: Takeda; Research Support: Takeda; Non-profit organizations: Presidency of the EBMT. EP: Takeda, Recordati, Helsinn, Kyowa Kirin, Novartis, UCB, Leo, Abbvie, Jansen. PLOR: Honoraria: Takeda, Kyowa Kirin, Helsinn, Recordati Rare Diseases. Travel support: UCB, Kyowa Kirin, Recordati Rare Diseases, Novartis. ALR: none reported. ISO: none reported. JS: Honoraria & Consultancy Helsinn, Recordati, Takeda, Therakos, Kyowa Kirin. IYA: Honoraria: Novartis, BMS, Kite/Gilead, Janssen and Pfizer. FO: Honoraria: Takeda, MEDAC Pharma, Kyowa Kirin; Travel support: Takeda, Jazz Pharma, Kyowa Kirin; NS: Travel support: Beigene, Roche, Stocks: BMS.
